

## Oncolmmunin Incorporated

[View the current Oncolmmunin Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/7809-Oncolmmunin+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/7809-Oncolmmunin+Incorporated.html>)

### Contact Details:

**207A Perry Parkway, Suite 6**  
**Gaithersburg**  
**MD**  
**20877**  
**United States of America**

Tel: (301) 987-7881  
Fax: (301) 987-7882  
Email: [info@phiphilux.com](mailto:info@phiphilux.com)

Oncolmmunin, Inc. was founded by Dr. Akira Komoriya and Dr. Beverly Packard in 1994. The Company has been issued two U.S. patents on its proprietary design for protease inhibitors and fluorogenic substrates. The first PCT application has now entered into national phases in Japan and Europe and a second PCT was filed in 1998.

Oncolmmunin, Inc. has designed, synthesized, validated, and patented a new class of protease substrates. Unique aspects of these molecules are: (1) incorporation of amino acid sequence information from both sides of protease cleavage sites (up to ten amino acid residues), thereby providing not only linear but three-dimensional specificity for proteases and (2) ability to cross intact cell membranes enabling measurement and inhibition of intracellular protease activities in living cells. Exploitation of elements of this latter point form the basis for Oncolmmunin's patented design for the therapeutic delivery of peptide-based protease inhibitors as well as peptide-based inhibitors of other intracellular targets in sizes ranging up to twenty amino acids.

### Recent Publications by Oncolmmunin Incorporated:



- [Intracellular protease activation in apoptosis and cell-mediated cytotoxicity characterized by cell-permeable fluorogenic protease substrates.](#)  
*Over the past decade the importance of signaling from reporter molecules...*26th March, 2008  
Oncolmmunin Inc5., 207A Perry Parkway, Suite 6, Gaithersburg, MD 20877,- Cell Res. 2008 Feb;18(2):238-47. ([DOI Direct Link](#))
- [Granzyme B activity in target cells detects attack by cytotoxic lymphocytes.](#)  
*Lymphocyte-mediated cytotoxicity via granule exocytosis operates by the...*6th November, 2007  
Oncolmmunin,- J Immunol. 2007 Sep 15;179(6):3812-20.
- [Assessment of caspase activities in intact apoptotic thymocytes using cell-permeable fluorogenic](#)

[caspase substrates.](#)

*To detect caspase activities in intact apoptotic cells at the single cell...*6th August, 2000

Oncolmmunin, Incorporated, Gaithersburg, MD 20877, USA.- J Exp Med. 2000 Jun 5;191(11):1819-28.



### Oncolmmunin Incorporated Patents:

- 6037137- [Fluorogenic peptides for the detection of protease activity](#)
- 5714342- [Compositions for the detection of protease in biological samples and methods of use thereof](#)
- 5605809- [Compositions for the detection of proteases in biological samples and methods of use thereof](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies.](#)

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

